Skip to content

Author

Muhammad M. Elsharkawy

We have 3 of 22 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review

Alzheimer’s Disease: From Molecular Pathogenesis to Disease-Modifying Therapies and Clinical Implementation in Aging Populations

This comprehensive review synthesizes current knowledge across the full spectrum of AD, encompassing molecular pathophysiology (amyloid cascade, tau hyperphosphorylation, and neuroinflammation), genetic architecture, genetic architecture (familial mutations and APOE-mediated risk), evolving biomarker-based diagnostic f...

Azzam Zrineh, Rami Akwan, Roaa Darawsheh et al. · 0 citations
Review Oct 2026

Efficacy and Safety of Recaticimab in Patients With Dyslipidemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials With GRADE Assessment.

Low-density lipoprotein cholesterol (LDL-C) is the principal target for preventing atherosclerotic cardiovascular disease, yet many patients do not reach treatment goals with statins, and established proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies require injections every 2-4 weeks. Recaticimab is a hu...

Ahmed Talkhan, Amr M. Abou Elezz, N. Borham et al. · 0 citations
Review Sep 2026

Efficacy and Safety of Ongericimab in Patients With Dyslipidemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials With GRADE Assessment.

Ongericimab is a humanized monoclonal antibody against proprotein convertase subtilisin/kexin type 9 that reduces LDL-C and increases apolipoprotein A1 and high-density lipoprotein cholesterol and increased apolipoprotein A1 and high-density lipoprotein cholesterol (all P < 0.0001).

Ahmed Talkhan, M. Elkasaby, Ahmed S. A. Osman et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.